News

Dr. Bruce Riser, the CEO of BLR Bio  presented at the Festival of Biologics USA 2024 in San Diego California.  The topic of presentation was “Can Targeting Specific Myofibroblasts with Novel Therapeutics Treat/Cure a Spectrum of Fibro-Inflammatory Diseases and Cancers?”   This included  a description of leading edge work underway by BLR bio in conjunction with experts at the university of Saskatchewan involving  scRNA sequencing of fibroblast populations over the development of diseases and assessing proteomics from animal and human cell models. BLR also lead a roundtable discussion around identifying the causes for the historic large number of failed drug candidates in the fibrosis field.    

BLR Bio announces the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation for BLR 200 for the treatment of systemic sclerosis (SSc).    BLR-200 is novel and addresses multiple disease-supporting elements or redundancies in the pathways to initiation and progression and targets a key scar-forming myofibroblast cell. 

BLR Bio, released new animal data on its novel cancer therapy recently at the 7th annual Labroots  Drug Discovery and Development conference, in a presentation entitled  “BLR-100: Can a Novel Tumor Stroma Targeting Agent Reduce Chemotherapy Load as a Potential Effective Combination Therapy,”  Dr. Bruce Riser the CEO stated- This study supports the idea that the use of BLR’s compound — BLR-100 — could provide similar efficacy to a doubling of the dose of existing chemotherapy without increasing side effects of these therapeutics, which often impact patient quality of life during treatment." 

New data on BLR Bio’s lead therapeutic BLR-200 is presented at the Keystone Symposium-Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies in Banff, AB, Canada.  Entitled- CCN3-derived peptide BLR-200 impairs bleomycin-induced skin fibrosis in a model of human scleroderma, the data demonstrated the ability of the drug to impair skin fibrosis by working down multiple molecular pathways, and involving myofibroblasts thought to be key to the progression and regression of disease. 

BLR Bio LLC, in collaboration with Dr. Andrew Leask and his team at University of Saskatchewan received an International Research Partnership Fund grant from the University of Saskatchewan titled “BLR-200 :A novel Treatment for Fibrotic Disease”. This work will run from April 1, 2022 until August, 2024.  BLR Bio will serve as the International partner supplying the drug to be evaluated as well as its expertise in animal model and drug development.  

BLR Bio presents at the Festival of Biologics USA conference in San Diego, CA sharing information on the company’s cancer asset BLR-100, a CAFs (Cancer Activated Fibroblasts) targeting therapy.

BLR Bio announces pre-clinical study of the effect of BLR-200 on Interstitial Lung Disease (ILD) have been initiated to determine the therapeutic effect on markers of fibrosis in the lung.

BLR Bio announces pursuit of proteonomics analysis of its peptides in two diseases of very high medical need, Scleroderma (systemic sclerosis) and non-alcoholic steatohepatitis (NASH) disease, the latter under an NIH Phase 1 Small Business Innovative Grant .   BLR is working closely with world expert collaborators from both the University of Michigan and the University of Saskatchewan.  This leading-edge research will provide deep insights into both the pathways driving these disease as well as mode of action of the BLR therapeutics peptides.

BLR Bio LLC. announces results from preclinical studies demonstrating the potential role in the treatment of Pancreatic Cancer of the company’s CCN- Based Therapeutic Peptides.  The studies were published in Cells 2020, 9(4), 952 titled “CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy”. 

BLR Bio LLC announces initiation of work on the company’s CCN based diagnostic in an application for NASH as part of an NIH funded grant.   The company is partnering with a leader in the diagnostics area based in Europe.  

“Preclinical data on BLR Bio’s drug candidate BLR-200 is presented at the Victoria conference .   The presentation abstract demonstrates that BLR-200 has a significant effect on the progression of key markers of injury/fibrosis in the skin in the bleomycin-induced murine model of systemic sclerosis.   

“Dr. Riser presents current data on its liver injury program entitled  “CCN3-based Peptide Inhibits/Reverses Liver Injury in a Mouse Model of Diabetes and Obesity” at the Keystone Symposia, Obesity and NAFLD: Mechanism and Therapeutics,  in Banff, AB, Canada.